Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

The study duration per participant: * Screening period was 3-5 weeks * Placebo-controlled treatment period was 52 weeks for first approximately 960 randomized participants, and 24 to 52 weeks for potential additional randomized participants * Post-investigational medicinal product (IMP) treatment follow-up period was 20 weeks for participants not transitioning to the extension study LTS18133 (NCT06208306) Note: A long-term, double-blinded extension study had been implemented to allow participants in this study to continue receiving active IMP for an additional period. Only participants completing their End-of-Treatment (EOT) visit per this study protocol was offered to participate in the LTS18133 study (NCT06208306).